Tuberculosis Drug Names Supplied Free Under India's NTEP

This guide covers each drug name, why NTEP uses fixed-dose combinations, the newer second-line drugs India has adopted, and how free access actually works.

What are the first-line tuberculosis drug names used in India?

Isoniazid, rifampicin, pyrazinamide and ethambutol, often abbreviated HRZE, make up the standard first-line regimen for drug-sensitive TB, combined into a single fixed-dose combination tablet during the intensive phase rather than dispensed as four separate pills NTEP guidelines. The continuation phase uses a narrower combination of these same drugs.

Why does NTEP combine these four drug names into one fixed-dose tablet instead of four separate pills?

A fixed-dose combination tablet is a deliberate adherence-improving choice: a patient is less likely to skip one component of a single combined tablet than to selectively skip one pill out of four taken separately, which matters enormously given TB treatment's multi-month duration and India's population-scale patient volume under this programme.

What second-line tuberculosis drug names does India use for drug-resistant TB?

Bedaquiline and delamanid are newer second-line drugs NTEP has adopted into shorter, WHO-aligned regimens for drug-resistant TB, replacing older, longer and more toxic second-line drug combinations where the newer drugs are appropriate for the specific resistance pattern identified through laboratory testing.

Are these tuberculosis drug names supplied free in India, and does that depend on where a patient is diagnosed?

Yes. All NTEP-listed first-line and second-line tuberculosis drug names are supplied free through the Nikshay platform to any diagnosed patient, whether diagnosed in a government facility or a private clinic that notifies the case to the programme as legally required Nikshay platform. This free-access model removes drug cost as a barrier regardless of where a patient first sought care.

Why does private-sector case notification matter for whether a patient actually receives these free drugs?

A patient diagnosed by a private practitioner only connects to Nikshay's free-drug supply if that practitioner notifies the case to the programme, a legal requirement not always consistently followed. Without notification, a patient may end up purchasing first-line TB drugs privately despite being entitled to receive the exact same drug names free through NTEP.

Are bedaquiline and delamanid available at every hospital pharmacy, or only at designated centres?

No, not at every pharmacy. These newer second-line drugs are more centrally controlled and distributed through designated drug-resistant TB treatment centres rather than every participating facility, reflecting both lower patient volume and the additional clinical monitoring these drugs require compared with first-line FDC tablets.

What should a hospital pharmacy know before stocking any of these tuberculosis drug names independently?

A hospital pharmacy can generally stock first-line FDC tablets as part of standard NTEP participation, but should confirm its designated-centre status with the programme before attempting to independently stock second-line drugs like bedaquiline, since these are typically distributed through a controlled, centre-specific supply chain rather than open pharmacy procurement.

Why does reliable stocking of these specific drug names matter operationally for a hospital?

NTEP's DOTS delivery model depends on consistent local availability of the correct first-line FDC tablets, and a hospital benefits from a pharmacy that reliably stocks and tracks these drug names alongside its Nikshay notification and reporting obligations. Managed hospital pharmacy services and pharmacy inventory management for expiry and dead stock cover how in-house stocking discipline supports this kind of programme-aligned drug availability in practice.

What monitoring does each first-line drug require given its specific side-effect profile?

Isoniazid and rifampicin both carry a documented hepatotoxicity risk, and NTEP protocol includes baseline and periodic liver function monitoring, particularly for patients with pre-existing liver disease or heavy alcohol use, since drug-induced liver injury is one of the more serious adverse events in first-line therapy. Ethambutol carries a specific risk of optic neuritis at higher doses or with impaired renal clearance, warranting visual monitoring for patients on extended courses.

Rifampicin also induces hepatic enzymes that affect the metabolism of several co-prescribed drugs, including some antiretrovirals and oral contraceptives, meaning any patient starting first-line TB treatment needs their full medication list reviewed for this specific interaction rather than assuming rifampicin is metabolically inert alongside other prescriptions.

Why does rifampicin's drug-interaction profile matter so much for hospital pharmacy medication review?

Rifampicin is one of the more potent enzyme-inducing drugs in common clinical use, meaningfully lowering blood levels of numerous co-administered medications by accelerating their metabolism, distinct from the direct pharmacodynamic interactions seen with many other drug classes.

A hospital pharmacy dispensing rifampicin-containing TB therapy to a patient already on other chronic medication needs to flag this interaction specifically. The consequence is often a co-prescribed drug becoming under-dosed rather than an acute, immediately visible reaction the patient would notice right away.

This is a genuine medication-reconciliation task at TB treatment initiation, not an afterthought: a patient starting first-line TB therapy while also managing HIV, epilepsy, or hormonal contraception needs that overlap actively reviewed, since rifampicin's interaction profile can silently undermine the effectiveness of the other therapy without an obvious warning sign.

How does delamanid differ from bedaquiline as a second-line drug-resistant TB option?

Delamanid and bedaquiline work through different mechanisms and are sometimes combined for particularly resistant cases. Specific choice depends on the patient's resistance pattern, prior history and tolerability, as decided by the specialist team at a designated centre. Both represent a meaningfully shorter and generally better-tolerated option compared with the older, more toxic second-line regimens they have progressively replaced under updated WHO-aligned national guidance.

Neither drug is typically initiated outside a designated centre with the specialist oversight and monitoring infrastructure these regimens require, which is a deliberate programmatic safeguard given the real complexity of dosing and monitoring drug-resistant TB therapy correctly over its full extended course.

What should a hospital pharmacy's TB drug name stocking checklist include?

A working checklist confirms reliable stocking of the HRZE fixed-dose combination for standard first-line therapy, a documented rifampicin drug-interaction check built into every TB treatment initiation, confirmed designated-centre status before stocking bedaquiline or delamanid, and consistent Nikshay case notification so patients actually receive these drug names free rather than being billed privately for medication the programme already covers.

Do generic versions of these tuberculosis drug names exist alongside NTEP's free supply?

Generic isoniazid, rifampicin, pyrazinamide and ethambutol are all manufactured domestically by multiple Indian companies, and while NTEP's free supply covers the programme's own patients, these generics are also available through normal commercial pharmaceutical channels for cases outside the programme's direct reach, such as private treatment not yet notified to Nikshay.

Sources

1. 1National TB Elimination Programme guidelines — Central TB Division, Ministry of Health and Family Welfare
2. 2Nikshay platform — Central TB Division, Government of India
3. 3World Health Organization consolidated guidelines on tuberculosis treatment — World Health Organization
4. 4Central Drugs Standard Control Organisation — Drugs and Cosmetics Act, 1940 and Rules, 1945

This article is for informational purposes and is not a substitute for professional medical advice. TB treatment must be managed under NTEP/DOTS supervision by a qualified physician.